Monogenic Diabetes • Precision Endocrine CarePANEL-MET-16

Metabolic & Monogenic Diabetes Panel

Up to 5% of patients diagnosed with Type 2 diabetes actually have Monogenic Diabetes (MODY), an inherited single-gene disorder. Correct genetic classification can allow patients to transition from daily insulin injections to simple, well-tolerated oral sulfonylurea tablets, dramatically improving blood sugar control and quality of life.

Metabolic Genes16 Biomarkers

Diagnostic ImpactMedication Shift

Turnaround Time7–10 Days

Accuracy99.9%

Check If You Qualify

Takes under 2 minutes • Quick Pre-Qualification

Check Eligibility →

HIPAA 256-Bit Encrypted

Who Should Consider This Screening?

Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:

Diabetes diagnosed at a younger age (<35 years) with normal body mass index (BMI).

Diabetes spanning three consecutive generations in the family lineage.

Absence of typical Type 2 diabetes characteristics (no obesity, normal lipid profile).

Negative pancreatic islet autoantibodies (ruling out classic Type 1 diabetes).

Mild, persistent fasting elevated blood sugar that remains stable over decades.

Biomarkers & Genes Evaluated in this Panel

Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.

Gene Symbol / Name	Clinical Significance	Actionable Impact
HNF1A & HNF4AHepatocyte Nuclear Factor 1 & 4 Alpha (MODY 3 & 1)	Regulates pancreatic beta-cell insulin secretion response to glucose.	Allows clinical transition from insulin to low-dose oral sulfonylureas with superior glycemic control.
GCKGlucokinase Pancreatic Glucose Sensor (MODY 2)	Controls the baseline fasting glucose threshold in liver and pancreas.	Confirms benign, stable mild hyperglycemia that typically requires zero medication, avoiding overtreatment.
PPARG & KCNJ11Insulin Sensitivity & Potassium Channel Subunits	Modulates peripheral insulin resistance and neonatal/atypical diabetes pathogenesis.	Directs personalized selection of GLP-1, SGLT-2, or oral hypoglycemic medication classes.

Sample Report & Diagnostic Action Plan

Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.

Sample Result ClassificationPathogenic Variant Identified

Identified Finding:

Heterozygous pathogenic mutation identified in HNF1A (c.872dupC, p.Pro291fs) confirming MODY 3.

Clinician Recommendation:

Discuss with endocrinologist for potential transition from insulin therapy to oral low-dose glimepiride/gliclazide with continuous glucose monitoring.

Clinical Care & Laboratory Standards

How our licensed physician network and accredited laboratories deliver personalized diagnostic clarity to your doorstep:

100% Physician-Ordered & CLIA Lab Certified

Physician-ordered metabolic genetic analysis sequences 16 pancreatic biomarkers to differentiate Monogenic Diabetes (MODY) from Type 2 diabetes and guide tailored therapy.

Our network of state-licensed physicians reviews your clinical indications to confirm medical necessity and coordinate care before any kit is mailed.

Physician-Ordered Clinical Screening

Ready to Check Your Eligibility for Metabolic & Monogenic Diabetes Panel?

Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed

Start 2-Minute Pre-Qualification →